
    
      This is a multicenter, randomized, double-blind, double-dummy, parallel-group study. Subjects
      who meet all the inclusion/exclusion criteria will be randomly assigned to 1 of 2 treatment
      groups, Rabeprazole Extended-Release (RAB ER) 50 mg or Esomeprazole (ESO) 40 mg for the
      treatment of mild to moderate erosive Gastroesophageal Reflux Disease (GERD).
    
  